Bicara Therapeutics (BCAX) Competitors $20.60 +0.17 (+0.81%) As of 11:23 AM Eastern This is a fair market value price provided by Massive. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock BCAX vs. RYTM, IMVT, CNTA, COGT, and SRRKShould you buy Bicara Therapeutics stock or one of its competitors? MarketBeat compares Bicara Therapeutics with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Bicara Therapeutics include Rhythm Pharmaceuticals (RYTM), Immunovant (IMVT), Centessa Pharmaceuticals (CNTA), Cogent Biosciences (COGT), and Scholar Rock (SRRK). These companies are all part of the "pharmaceutical products" industry. BCAX vs. RYTMBCAX vs. IMVTBCAX vs. CNTABCAX vs. COGTBCAX vs. SRRKHow does Bicara Therapeutics compare to Rhythm Pharmaceuticals?Rhythm Pharmaceuticals (NASDAQ:RYTM) and Bicara Therapeutics (NASDAQ:BCAX) are both medical companies, but which is the better business? We will compare the two businesses based on the strength of their earnings, analyst recommendations, media sentiment, dividends, risk, valuation, profitability and institutional ownership. Which has stronger earnings and valuation, RYTM or BCAX? Bicara Therapeutics has lower revenue, but higher earnings than Rhythm Pharmaceuticals. Rhythm Pharmaceuticals is trading at a lower price-to-earnings ratio than Bicara Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioRhythm Pharmaceuticals$189.76M32.84-$196.54M-$3.13N/ABicara TherapeuticsN/AN/A-$137.95M-$2.78N/A Do analysts recommend RYTM or BCAX? Rhythm Pharmaceuticals currently has a consensus price target of $131.81, indicating a potential upside of 44.94%. Bicara Therapeutics has a consensus price target of $30.27, indicating a potential upside of 46.99%. Given Bicara Therapeutics' higher probable upside, analysts clearly believe Bicara Therapeutics is more favorable than Rhythm Pharmaceuticals.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Rhythm Pharmaceuticals 1 Sell rating(s) 2 Hold rating(s) 15 Buy rating(s) 1 Strong Buy rating(s) 2.84Bicara Therapeutics 1 Sell rating(s) 3 Hold rating(s) 9 Buy rating(s) 1 Strong Buy rating(s) 2.71 Is RYTM or BCAX more profitable? Bicara Therapeutics has a net margin of 0.00% compared to Rhythm Pharmaceuticals' net margin of -93.33%. Bicara Therapeutics' return on equity of -35.89% beat Rhythm Pharmaceuticals' return on equity.Company Net Margins Return on Equity Return on Assets Rhythm Pharmaceuticals-93.33% -203.25% -44.99% Bicara Therapeutics N/A -35.89%-33.78% Which has more volatility and risk, RYTM or BCAX? Rhythm Pharmaceuticals has a beta of 1.94, meaning that its share price is 94% more volatile than the broader market. Comparatively, Bicara Therapeutics has a beta of -0.57, meaning that its share price is 157% less volatile than the broader market. Does the media prefer RYTM or BCAX? In the previous week, Bicara Therapeutics had 10 more articles in the media than Rhythm Pharmaceuticals. MarketBeat recorded 10 mentions for Bicara Therapeutics and 0 mentions for Rhythm Pharmaceuticals. Rhythm Pharmaceuticals' average media sentiment score of 0.00 beat Bicara Therapeutics' score of -0.03 indicating that Rhythm Pharmaceuticals is being referred to more favorably in the media. Company Overall Sentiment Rhythm Pharmaceuticals Neutral Bicara Therapeutics Neutral SummaryBicara Therapeutics beats Rhythm Pharmaceuticals on 8 of the 13 factors compared between the two stocks.How does Bicara Therapeutics compare to Immunovant?Immunovant (NASDAQ:IMVT) and Bicara Therapeutics (NASDAQ:BCAX) are both medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their analyst recommendations, media sentiment, dividends, profitability, valuation, earnings, risk and institutional ownership. Which has higher earnings and valuation, IMVT or BCAX? Immunovant is trading at a lower price-to-earnings ratio than Bicara Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioImmunovantN/AN/A-$413.84M-$2.69N/ABicara TherapeuticsN/AN/A-$137.95M-$2.78N/A Do insiders and institutionals have more ownership in IMVT or BCAX? 47.1% of Immunovant shares are held by institutional investors. 1.8% of Immunovant shares are held by company insiders. Comparatively, 15.5% of Bicara Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth. Do analysts recommend IMVT or BCAX? Immunovant presently has a consensus price target of $34.44, indicating a potential upside of 4.48%. Bicara Therapeutics has a consensus price target of $30.27, indicating a potential upside of 46.99%. Given Bicara Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe Bicara Therapeutics is more favorable than Immunovant.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Immunovant 1 Sell rating(s) 4 Hold rating(s) 6 Buy rating(s) 0 Strong Buy rating(s) 2.45Bicara Therapeutics 1 Sell rating(s) 3 Hold rating(s) 9 Buy rating(s) 1 Strong Buy rating(s) 2.71 Which has more volatility and risk, IMVT or BCAX? Immunovant has a beta of 0.7, indicating that its share price is 30% less volatile than the broader market. Comparatively, Bicara Therapeutics has a beta of -0.57, indicating that its share price is 157% less volatile than the broader market. Does the media favor IMVT or BCAX? In the previous week, Immunovant had 7 more articles in the media than Bicara Therapeutics. MarketBeat recorded 17 mentions for Immunovant and 10 mentions for Bicara Therapeutics. Immunovant's average media sentiment score of 0.38 beat Bicara Therapeutics' score of -0.03 indicating that Immunovant is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Immunovant 8 Very Positive mention(s) 1 Positive mention(s) 5 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Neutral Bicara Therapeutics 2 Very Positive mention(s) 1 Positive mention(s) 5 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Neutral Is IMVT or BCAX more profitable? Bicara Therapeutics' return on equity of -35.89% beat Immunovant's return on equity.Company Net Margins Return on Equity Return on Assets ImmunovantN/A -63.17% -58.01% Bicara Therapeutics N/A -35.89%-33.78% SummaryBicara Therapeutics beats Immunovant on 9 of the 14 factors compared between the two stocks.How does Bicara Therapeutics compare to Centessa Pharmaceuticals?Bicara Therapeutics (NASDAQ:BCAX) and Centessa Pharmaceuticals (NASDAQ:CNTA) are both medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their valuation, risk, media sentiment, dividends, institutional ownership, analyst recommendations, profitability and earnings. Which has more risk and volatility, BCAX or CNTA? Bicara Therapeutics has a beta of -0.57, meaning that its share price is 157% less volatile than the broader market. Comparatively, Centessa Pharmaceuticals has a beta of 1.13, meaning that its share price is 13% more volatile than the broader market. Is BCAX or CNTA more profitable? Bicara Therapeutics' return on equity of -35.89% beat Centessa Pharmaceuticals' return on equity.Company Net Margins Return on Equity Return on Assets Bicara TherapeuticsN/A -35.89% -33.78% Centessa Pharmaceuticals N/A -60.37%-44.17% Does the media favor BCAX or CNTA? In the previous week, Bicara Therapeutics had 10 more articles in the media than Centessa Pharmaceuticals. MarketBeat recorded 10 mentions for Bicara Therapeutics and 0 mentions for Centessa Pharmaceuticals. Centessa Pharmaceuticals' average media sentiment score of 0.00 beat Bicara Therapeutics' score of -0.03 indicating that Centessa Pharmaceuticals is being referred to more favorably in the news media. Company Overall Sentiment Bicara Therapeutics Neutral Centessa Pharmaceuticals Neutral Do insiders & institutionals have more ownership in BCAX or CNTA? 82.0% of Centessa Pharmaceuticals shares are held by institutional investors. 15.5% of Bicara Therapeutics shares are held by insiders. Comparatively, 4.1% of Centessa Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term. Do analysts recommend BCAX or CNTA? Bicara Therapeutics presently has a consensus target price of $30.27, suggesting a potential upside of 46.99%. Centessa Pharmaceuticals has a consensus target price of $40.70, suggesting a potential upside of 2.27%. Given Bicara Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Bicara Therapeutics is more favorable than Centessa Pharmaceuticals.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Bicara Therapeutics 1 Sell rating(s) 3 Hold rating(s) 9 Buy rating(s) 1 Strong Buy rating(s) 2.71Centessa Pharmaceuticals 1 Sell rating(s) 9 Hold rating(s) 4 Buy rating(s) 0 Strong Buy rating(s) 2.21 Which has higher earnings and valuation, BCAX or CNTA? Centessa Pharmaceuticals is trading at a lower price-to-earnings ratio than Bicara Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioBicara TherapeuticsN/AN/A-$137.95M-$2.78N/ACentessa PharmaceuticalsN/AN/A-$197.53M-$1.79N/A SummaryBicara Therapeutics beats Centessa Pharmaceuticals on 10 of the 14 factors compared between the two stocks.How does Bicara Therapeutics compare to Cogent Biosciences?Bicara Therapeutics (NASDAQ:BCAX) and Cogent Biosciences (NASDAQ:COGT) are both medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their media sentiment, valuation, risk, analyst recommendations, dividends, earnings, profitability and institutional ownership. Which has better earnings and valuation, BCAX or COGT? Cogent Biosciences is trading at a lower price-to-earnings ratio than Bicara Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioBicara TherapeuticsN/AN/A-$137.95M-$2.78N/ACogent BiosciencesN/AN/A-$328.94M-$2.17N/A Do analysts rate BCAX or COGT? Bicara Therapeutics currently has a consensus price target of $30.27, suggesting a potential upside of 46.99%. Cogent Biosciences has a consensus price target of $43.73, suggesting a potential upside of 34.01%. Given Bicara Therapeutics' higher probable upside, research analysts plainly believe Bicara Therapeutics is more favorable than Cogent Biosciences.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Bicara Therapeutics 1 Sell rating(s) 3 Hold rating(s) 9 Buy rating(s) 1 Strong Buy rating(s) 2.71Cogent Biosciences 1 Sell rating(s) 2 Hold rating(s) 9 Buy rating(s) 2 Strong Buy rating(s) 2.86 Is BCAX or COGT more profitable? Bicara Therapeutics' return on equity of -35.89% beat Cogent Biosciences' return on equity.Company Net Margins Return on Equity Return on Assets Bicara TherapeuticsN/A -35.89% -33.78% Cogent Biosciences N/A -104.27%-54.64% Does the media refer more to BCAX or COGT? In the previous week, Bicara Therapeutics had 10 more articles in the media than Cogent Biosciences. MarketBeat recorded 10 mentions for Bicara Therapeutics and 0 mentions for Cogent Biosciences. Cogent Biosciences' average media sentiment score of 0.00 beat Bicara Therapeutics' score of -0.03 indicating that Cogent Biosciences is being referred to more favorably in the news media. Company Overall Sentiment Bicara Therapeutics Neutral Cogent Biosciences Neutral Which has more risk & volatility, BCAX or COGT? Bicara Therapeutics has a beta of -0.57, meaning that its share price is 157% less volatile than the broader market. Comparatively, Cogent Biosciences has a beta of 0.37, meaning that its share price is 63% less volatile than the broader market. SummaryBicara Therapeutics beats Cogent Biosciences on 6 of the 11 factors compared between the two stocks.How does Bicara Therapeutics compare to Scholar Rock?Scholar Rock (NASDAQ:SRRK) and Bicara Therapeutics (NASDAQ:BCAX) are both medical companies, but which is the superior business? We will compare the two companies based on the strength of their risk, media sentiment, valuation, earnings, dividends, institutional ownership, profitability and analyst recommendations. Is SRRK or BCAX more profitable? Bicara Therapeutics' return on equity of -35.89% beat Scholar Rock's return on equity.Company Net Margins Return on Equity Return on Assets Scholar RockN/A -163.52% -96.67% Bicara Therapeutics N/A -35.89%-33.78% Does the media prefer SRRK or BCAX? In the previous week, Bicara Therapeutics had 1 more articles in the media than Scholar Rock. MarketBeat recorded 10 mentions for Bicara Therapeutics and 9 mentions for Scholar Rock. Scholar Rock's average media sentiment score of 0.59 beat Bicara Therapeutics' score of -0.03 indicating that Scholar Rock is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Scholar Rock 3 Very Positive mention(s) 0 Positive mention(s) 6 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Bicara Therapeutics 2 Very Positive mention(s) 1 Positive mention(s) 5 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Neutral Which has higher earnings and valuation, SRRK or BCAX? Scholar Rock is trading at a lower price-to-earnings ratio than Bicara Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioScholar RockN/AN/A-$377.94M-$3.59N/ABicara TherapeuticsN/AN/A-$137.95M-$2.78N/A Do insiders and institutionals hold more shares of SRRK or BCAX? 91.1% of Scholar Rock shares are held by institutional investors. 13.3% of Scholar Rock shares are held by company insiders. Comparatively, 15.5% of Bicara Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term. Do analysts rate SRRK or BCAX? Scholar Rock presently has a consensus target price of $56.00, indicating a potential upside of 20.22%. Bicara Therapeutics has a consensus target price of $30.27, indicating a potential upside of 46.99%. Given Bicara Therapeutics' higher possible upside, analysts clearly believe Bicara Therapeutics is more favorable than Scholar Rock.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Scholar Rock 1 Sell rating(s) 0 Hold rating(s) 12 Buy rating(s) 5 Strong Buy rating(s) 3.17Bicara Therapeutics 1 Sell rating(s) 3 Hold rating(s) 9 Buy rating(s) 1 Strong Buy rating(s) 2.71 Which has more risk & volatility, SRRK or BCAX? Scholar Rock has a beta of 0.7, indicating that its stock price is 30% less volatile than the broader market. Comparatively, Bicara Therapeutics has a beta of -0.57, indicating that its stock price is 157% less volatile than the broader market. SummaryBicara Therapeutics beats Scholar Rock on 8 of the 14 factors compared between the two stocks. Get Bicara Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for BCAX and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding BCAX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart BCAX vs. The Competition ExportMetricBicara TherapeuticsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$1.35B$3.32B$6.29B$12.20BDividend YieldN/A2.32%2.80%5.36%P/E Ratio-7.4118.6420.8125.32Price / SalesN/A272.96520.4371.72Price / CashN/A125.3543.1855.00Price / Book2.636.809.906.96Net Income-$137.95M$24.18M$3.54B$334.92M7 Day Performance-0.27%-1.09%-0.48%-1.24%1 Month Performance-10.88%-2.07%-0.82%0.27%1 Year Performance41.16%60.63%33.62%33.19% Bicara Therapeutics Competitors List ExportCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)BCAXBicara Therapeutics2.1757 of 5 stars$20.60+0.8%$30.27+47.0%+35.8%$1.35BN/AN/A32Insider TradeRYTMRhythm Pharmaceuticals2.0528 of 5 stars$91.31+4.5%$131.81+44.4%+41.9%$5.99B$189.76MN/A140IMVTImmunovant1.1476 of 5 stars$28.65-1.4%$32.44+13.2%+137.1%$5.91BN/AN/A120Trending NewsEarnings ReportAnalyst ForecastInsider TradeCNTACentessa Pharmaceuticals1.5061 of 5 stars$39.61+0.1%$40.70+2.8%+201.1%$5.91B$15MN/A200COGTCogent Biosciences2.2501 of 5 stars$34.53+1.3%$43.73+26.6%+520.0%$5.83BN/AN/A80Positive News Related Companies and Tools Related Companies RYTM Competitors IMVT Competitors CNTA Competitors COGT Competitors SRRK Competitors XENE Competitors GRFS Competitors APLS Competitors APGE Competitors CRSP Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:BCAX) was last updated on 5/21/2026 by MarketBeat.com Staff. From Our PartnersSpaceX eyes a 1.75 trillion valuation - here's what to knowElon Musk's team has quietly filed confidential paperwork with the SEC for what Bloomberg estimates could be a...Brownstone Research | SponsoredIran's New Leader Just Said Something That Should Terrify Every AmericanIran's Supreme Leader has declared the Strait of Hormuz closed as leverage against the U.S. - and with 40% of ...American Alternative | Sponsored$30 stock to buy before Starlink goes public (WATCH NOW!)In the next 3 minutes… James Altucher – legendary investor and venture capitalist… And someone who’s kno...Paradigm Press | SponsoredTrump's gold order: the announcement they won't put on the front pageOn August 15, 1971, Nixon interrupted prime-time television and ended the gold standard in 15 minutes - no deb...Reagan Gold Group | SponsoredMy feud with Zohran MamdaniEmmy-winning analyst releases his next big story Whitney Tilson shocked the nation on 60 Minutes when he ac...Stansberry Research | SponsoredIran War Shock: What I Was Told In That Private MeetingYou’re Being LIED To About The Iran War Forget EVERYTHING you’ve heard about the Iran war. Especially th...Banyan Hill Publishing | SponsoredWhy this tiny stock may move before the SpaceX IPO dropsThe projected SpaceX and xAI S-1 filing hits the SEC on June 1st - and analyst Dylan Jovine says $1.75 trillio...Behind the Markets | SponsoredYour book attachedBill Poulos is giving away his 'Safe Trade Options Formula' book for free - but only for a limited time throug...Profits Run | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Bicara Therapeutics Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Bicara Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
